Board of Directors

David G Lowe, Ph.D.

Co-founder, Chairman and Chief Executive Officer

As a scientist, venture capitalist and entrepreneur Dr Lowe’s career has centered on discovery and innovation in life sciences. Most recently Dr. Lowe was an investor, advisor, and Vice Chair of the Board of Shattuck Labs (NASDAQ: STTK), a biotechnology company developing novel bifunctional fusion proteins. As co-founder and CEO of Austin based Aeglea BioTherapeutics (NASDAQ: AGLE), he led the company into clinical trials in oncology and enzyme replacement therapy for genetic rare disease. As a venture capitalist at Skyline Ventures Dr Lowe worked on building and investing in therapeutic, diagnostic, and research tools companies. Starting his career at Genentech Inc., he became a Research Director with responsibility for small molecule and biologic drug discovery programs. Dr Lowe received a BS and PhD in Biochemistry from the University of Toronto, Canada

Everett Stone, Ph.D.

Co-founder and Chief Scientific Officer

Dr Stone is a Research Professor at the University of Texas at Austin and is an experienced cancer biologist and drug developer specializing in enzyme therapeutics for cancer (immuno)therapy and for the treatment of rare genetic diseases.  Prior to co-founding Delta Therapeutics Everett scientifically co-founded Aeglea Biotherapeutics and Ikena Oncology who are currently progressing several therapeutic enzymes he (co)invented through Phase I-III clinical trials. He received his B.A. degree from Drury University and his Ph.D. from UT Austin where he was named the “Emerging Inventor of the Year” in 2017 for his translational work.

Cynthia Lavoie DeltaTPX

Cynthia Lavoie, Ph.D.

Co-founder and Board Director

Cynthia Lavoie is a co-founder and board director of Delta TpX. As well as her role as one of the Managing Directors of AllosteRx Capital, an early-stage venture capital firm she co-founded in 2018, Cynthia is currently President and Chief Investment Officer of CCRM Enterprises Inc., with responsibility for the investment portfolio and the team. Prior to co-founding AllosteRx, Cynthia was a General Partner with TVM Capital, a global fund with main offices in Munich and Montreal. Cynthia has been on the boards of  Cytochroma (acquired by OPKO Health), VisualSonics (acquired by SonoSite, now FujiFilm SonoSite), and Trillium Therapeutics, acquired by Pfizer. Cynthia is currently a board director at Fibrocor Therapeutics, a fibrosis company in Toronto and a medical devices company Profound Medical (NASDAQ:PROF; TSX: PRN). Dr Lavoie received a PhD from McGill University and MBA from the University of Toronto.

Aaron Schuchart

Co-founder and Board Director

Mr. Schuchart has over twenty-five years of experience in key leadership roles for both large multinationals and small biotech companies, including Amgen, Novartis Diagnostics/Grifols, and Coherus Biosciences. He is currently Chief Business Officer of Lumos Pharma, a publicly traded biotech company focused on rare disease. He has successfully enabled new venture creation through corporate development initiatives, leading strategic and financing transactions to advance scientific and business goals. Throughout his tenure in the industry, Mr. Schuchart has led or advised on over 30 transactions totaling over $15 billion; developed and executed portfolio strategies for various technology platforms, therapeutic areas and markets toward the achievement of strong operating and financial growth performance for biopharmaceuticals and diagnostics businesses. Mr. Schuchart received a B.B.A. in Accounting from Texas Tech University and an M.B.A. from UCLA Anderson School of Management. He is a Certified Licensing Professional and is licensed as a Certified Public Accountant.

Jason Zhang

Board Observer

Dr. Jason Zhang is currently the Head-Corporate Venture Fund, at JSR Life Sciences.He has more than twenty years of experience in multiple industries, including medical research, investment banking, biotech and pharmaceutical. From 2017 to 2021, He was aManaging Director of International Investment and Business Development at Humanwell Healthcare Group, and from 2018 to 2021 Chief Operating Officer of both Humanwell Healthcare USA, LLC and PuraCap Pharmaceuticals, both subsidiaries of Humanwell. Previously he has been the head of North America Business Development of Yunkang Group (DaAn Health Group), a China-based healthcare company, and a Senior Vice President of Medisun Holdings, a Hong Kang-based investment firm.He has been a sell-side equity analyst at firms including Bank of Montreal Capital Markets, Prudential Equity Group and Stephens Group, among others, providing extensive coverage of biotech companies of various market capitalization ranges and therapeutic areas.He has also been involved in IPO, follow-on financing and other investment banking activities.Prior to his career on Wall Street, Dr. Zhang conducted research in Oncology at Eli Lilly and Company and Indiana University.He obtained his Ph.D. in Botanic Sciences (Plant Pathology andCell, Molecular and Neurosciences) from University of Hawaii and MBA from Indiana University’s Kelly School of Business.